Thirman, M. J., Zwaan, C. M., Shukla, N., Cuglievan, B., Gu, Y., Bagley, R. G., Madigan, K., Chudnovsky, Y., Nguyen, H. V., McNeer, N., Wei, A., Fleming, S., Sabins, H., Aldoss, I., Kovacsovics, T., Stone, R., Arellano, M., Patel, M., Talati, C., Chen, J., Nachmias, B., Heiblig, M., Fernandez, P. M., Arnan-Sangerman, M., Stein, E. M., Mantzaris, I., Blachly, J. S., Traer, E., Zwaan, C. M., Wolach, O., Marconi, G., Bajel, A., Grove, C. S., Mannis, G. N., Schuh, A., Thirman, M., Byrd, J., McMahon, C. M., Dickens, D. S., Perl, A., Greenwood, M., Issa, G. C., Whitlock, J., Shami, P. J., DiPersio, J. (2025). Menin Inhibition With Revumenib for
                    <i>KMT2A</i>
                    -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00826